Investor Type | Firm |
Stages | Acquisition |
Investing | United States |
Investment Range | $2,000,000 - $65,000,000 |
Bear Stearns Health Innoventures L.P. was a private equity fund that operated as a subsidiary of the investment banking firm Bear Stearns & Co. Inc. The fund was dedicated to financing various stages of company growth, specializing in acquisition investments. With a minimum investment threshold of $2,000,000 and a maximum of $65,000,000, the fund aimed to support ventures within its focus areas. The fund's investment thesis revolved around identifying and exploiting opportunities in sectors where the team found a confluence of unique knowledge, relationships, and experience that allowed them to add substantial value beyond capital. As part of Bear Stearns & Co. Inc., Bear Stearns Health Innoventures L.P. benefited from the extensive capabilities and resources provided by the parent firm which was involved in corporate finance, mergers and acquisitions, fixed income sales and trading, asset management, and institutional equities among other areas. Bear Stearns & Co. Inc., founded in 1923 and headquartered in New York City, had a global presence with offices across the United States and major cities around the world, such as London, Beijing, Dublin, Hong Kong, and Tokyo. They offered a full range of financial services, including trading and research, private client services, derivatives, foreign exchange, and futures sales, and trading services, catering to an audience comprising governments, corporations, institutions, and individuals. The fund's strategy was likely aligned with the broader objectives and expertise areas of Bear Stearns & Co. Inc. Bear Stearns & Co. Inc. was acquired by J.P. Morgan Securities LLC on October 1, 2008, which expanded J.P. Morgan's wealth management and substantial wealth advisory capabilities. J.P. Morgan Wealth Advisors leverage their experience and firm resources to provide personalized solutions across banking, lending, investing, and wealth planning to clients, as indicated by the information on the J.P. Morgan website.